文献速递脑血管病

非维生素K拮抗剂口服抗凝药在肾功能超常的亚洲房颤患者中的应用

Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients With Supranormal Renal Function.
PubMed 文献 · Stroke · 2019-05-14

本研究基于韩国国民健康保险服务数据库,纳入CrCl>80 mL/min的非瓣膜性房颤口服抗凝药使用者,比较NOACs与华法林的有效性和安全性。结果显示,在CrCl>80 mL/min及>95 mL/min患者中,NOACs较华法林降低缺血性卒中及复合结局风险,且4种NOACs结果一致。

要点

  • 在CrCl>80 mL/min的亚洲房颤患者中,NOACs较华法林降低缺血性卒中风险(HR 0.51,95%CI 0.43-0.60)。
  • 复合结局风险亦降低(HR 0.64,95%CI 0.58-0.70),且在CrCl>95 mL/min患者中结果一致。
  • 利伐沙班、达比加群、阿哌沙班和艾多沙班四种NOACs均显示优于华法林的有效性和安全性。

核心结论

  • 在肾功能超常(CrCl>80 mL/min)的亚洲非瓣膜性房颤患者中,NOACs较华法林显示出更好的有效性和安全性。
  • 该获益在CrCl>95 mL/min患者中及全部4种NOACs中均一致观察。

研究设计与样本

  • 纳入CrCl>80 mL/min的非瓣膜性房颤新口服抗凝药使用者,包括利伐沙班6297例、达比加群4241例、阿哌沙班3395例、艾多沙班1187例和华法林9884例。
  • 采用倾向评分加权平衡组间协变量,以华法林为参照进行Cox回归分析。

主要发现

  • 汇合NOACs组较华法林降低缺血性卒中风险(HR 0.51,95%CI 0.43-0.60)和复合结局风险(HR 0.64,95%CI 0.58-0.70)。
  • 在CrCl>95 mL/min患者中,上述获益一致,且4种NOACs均降低缺血性卒中和复合结局风险。

临床怎么用

  • 对于肾功能超常(CrCl>80 mL/min)的亚洲房颤患者,NOACs可作为华法林的有效替代选择。
  • 在CrCl>95 mL/min患者中,NOACs仍显示较华法林更优的有效性和安全性,支持其在此类患者中的使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- In clinical trials, the reduced efficacy of non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention was reported for patients with nonvalvular atrial fibrillation with a creatinine clearance (CrCl) >95 mL/min compared with that of warfarin. We examined the effectiveness, safety, and net clinical benefit of NOACs compared with warfarin in Asian patients with atrial fibrillation and supranormal renal function. Methods- Using data from the Korean National Health Insurance Service database from January 2014 to December 2016, we included patients with nonvalvular atrial fibrillation with CrCl >80 mL/min. Among these incident oral anticoagulant users with rivaroxaban (n=6297), dabigatran (n=4241), apixaban (n=3395), edoxaban (n=1187), and warfarin (n=9884) were analyzed. Propensity score weighting was used to balance covariates across study groups. Hazard ratios for ischemic stroke, intracranial hemorrhage, gastrointestinal bleeding, major bleeding, all-cause death, and the composite outcome defined as ischemic stroke+intracranial hemorrhage+gastrointestinal bleeding+all-cause death were analyzed using Cox regression analysis with warfarin as the reference. Results- Baseline characteristics were well balanced among all groups (mean age, 66±11 years; 63% were men; mean CHA2DS2-VASc score, 3.0±1.8). Forty-five percent of the patients had CrCl >95 mL/min. Pooled NOACs yielded lower risks of ischemic stroke (hazard ratio, 0.51; 95% CI, 0.43-0.60) and the composite outcome (hazard ratio, 0.64; 95% CI, 0.58-0.70) than warfarin in patients with CrCl >80 mL/min. These benefits were consistent in those with CrCl >95 mL/min. All 4 NOACs reduced the risks of ischemic stroke and the composite outcome in both patients with CrCl >80 mL/min and >95 mL/min. Conclusions- The NOACs showed better effectiveness and safety than warfarin in the patients with atrial fibrillation and supranormal renal function; this was consistently observed for all 4 NOACs and in patients with CrCl >95 mL/min.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Lee SR, Choi EK, Han KD, et al. Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients With Supranormal Renal Function. Stroke. 2019. PMID: 31084339. doi:10.1161/STROKEAHA.118.024264

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。